| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > HRM: Contributing to Well-being or Ill-being at Work? |
|
Digg It - HRM: Contributing to Well-being or Ill-being at Work?
If you were to take the people out of an organisation you would be left with some stock and machinery that would be of little value, and possibly some property. It is the people that make an organisat According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ion function, so having the people functioning to the best of their ability must surely be best for an organisation. Yet much of what is undertaken in the field of HRM actually serves to detract from ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in eople functioning at their best. Evidence from studies of wellbeing in the workplace reveal some interesting findings that raise questions as to whether the current focus of HRM will adapt to the evol lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ing future workplace, or whether it will need to be redrawn along different lines, focussing on maintaining wellbeing above all else in the workplace to enable people to be successful for their organis here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe tions. Much of the literature on wellbeing focuses on work-life balance (WLB) as potentially the most important element that affects people and their behaviour at work. Hence it is the most high prof d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro le and most highly legislated area in consideration. However, the evidence in this area is mixed and far from conclusive. While a measure of organisational health is being heralded by the likes of H ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc nderson Fund Management to allow investors to make more informed decisions about the companies they are investing in, quite how this will be calculated, or what its value will be are yet to be determin easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ed. City analysts already take a keen interest in voluntary staff turnover rates, especially in service/consulting businesses where valuation is contingent on the ability of a business to scale quickl nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically and in high growth periods. They see voluntary turnover as a good but crude indicator of employee satisfaction and engagement. They also look to indices such as Gallup Q12 scores that measure engage and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ent. Other measures are emerging in the marketplace. Vielife, for example, has a range of organisational health audits both at the whole organisation and individual employee level, and aim to develop t ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi e standardised metric for the measurement of employee wellbeing. Ironically they find that a health and wellbeing index is higher on the agenda of the financial and managing directors’ than it is for ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a he HR director. The current UK Labour Government is also on the health and wellbeing bandwagon with its current white paper ‘Choosing Health’ devoting a whole chapter to workplace health and wellbeing dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod They claim that stress-related conditions and musculoskeletal disorders are now the commonest reported causes of work-related sickness absence, and that 3.74 million workers clock up more than the 48 cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin hour limit under the Working Time Directive, which is 423,000 more than in 1992 when there was no long hours protection. Work in this area by the CIPD and The Tomorrow Project has identified what appe tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ar to be four key characteristics that contribute to an individual’s wellbeing: autonomy, relationships, the physical environment and the individual’s disposition. This remodels HRM away from the tra t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel itional relations, resourcing, development and reward model which is functional and outcome based, to one where the individual becomes the central concern. Does the individual have the appropriate lev ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust l of autonomy to allow them to function best? Are the significant relationships in their work enhancing rather than detracting from their performance? Is the physical environment contributing to thei y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products productivity, or is it making them sick? How can the work environment be managed to ensure that it is a positive experience for people, contributing to a positive rather than negative disposition? A . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de guably any activity which does not contribute to any of these four is not contributing to the success of the individual, and hence the success of the organisation, and the organisation should therefore elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip question abandoning them. If you were to ask these questions with regard to the policies and practices that HRM currently employs, it would be interesting to see how many passed the test and remained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Knowledge Management Services: Organizing Knowledge For Businesses
|